Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Meibomian gland dysfunction Indication Strategy Report 2026: PPAR-gamma, Trials and Deals
23 July 2026
2026 Meibomian gland dysfunction strategy: epidemiology, PPAR-gamma biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sjögren dry eye disease Indication Strategy Report 2026: BAFF, Trials and Deals
23 July 2026
2026 Sjögren dry eye disease strategy: epidemiology, BAFF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Ocular cicatricial pemphigoid Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Ocular cicatricial pemphigoid strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Vogt-Koyanagi-Harada disease Indication Strategy Report 2026: IL-23, Trials and Deals
23 July 2026
2026 Vogt-Koyanagi-Harada disease strategy: epidemiology, IL-23 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sympathetic ophthalmia Indication Strategy Report 2026: TNF, Trials and Deals
23 July 2026
2026 Sympathetic ophthalmia strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Birdshot chorioretinopathy Indication Strategy Report 2026: IL-17A, Trials and Deals
23 July 2026
2026 Birdshot chorioretinopathy strategy: epidemiology, IL-17A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Coats disease Indication Strategy Report 2026: VEGFR2, Trials and Deals
23 July 2026
2026 Coats disease strategy: epidemiology, VEGFR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Familial exudative vitreoretinopathy Indication Strategy Report 2026: FZD4, Trials and Deals
23 July 2026
2026 Familial exudative vitreoretinopathy strategy: epidemiology, FZD4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Doyne honeycomb retinal dystrophy Indication Strategy Report 2026: EFEMP1, Trials and Deals
23 July 2026
2026 Doyne honeycomb retinal dystrophy strategy: epidemiology, EFEMP1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Juvenile X-linked retinoschisis Indication Strategy Report 2026: RS1, Trials and Deals
23 July 2026
2026 Juvenile X-linked retinoschisis strategy: epidemiology, RS1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Sorsby fundus dystrophy Indication Strategy Report 2026: TIMP3, Trials and Deals
23 July 2026
2026 Sorsby fundus dystrophy strategy: epidemiology, TIMP3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
North Carolina macular dystrophy Indication Strategy Report 2026: PRDM13, Trials and Deals
23 July 2026
2026 North Carolina macular dystrophy strategy: epidemiology, PRDM13 biology, clinical competition, recent deals, unmet need and market attractiveness.